SoFi CEO enters prepaid forward contract on 1.5 million shares
Investing.com - RBC Capital raised its price target on Edgewise Therapeutics (NASDAQ:EWTX) to $49.00 from $48.00 on Friday, maintaining an Outperform rating following the company’s second-quarter earnings report. According to InvestingPro data, analyst targets for EWTX range from $14 to $51, with 5 analysts recently revising their earnings estimates upward despite the stock’s 50.9% decline over the past six months.
The firm’s analysis indicates that all major catalysts for Edgewise remain on schedule, including the EDG-7500 12-week update in hypertrophic cardiomyopathy (HCM) expected in the fourth quarter of 2025.
RBC Capital noted that FDA alignment on a Duchenne muscular dystrophy (DMD) path forward is anticipated in the fourth quarter of 2025, while the company continues advancing toward a Phase III GRAND CANYON readout for Becker muscular dystrophy in the fourth quarter of 2026.
The investment firm believes the current share price undervalues all three of Edgewise’s therapeutic opportunities and sees significant long-term upside potential for the stock.
RBC Capital projects potential 2034 sales of $5 billion for Edgewise Therapeutics and recommends investors purchase the stock at current levels.
In other recent news, Edgewise Therapeutics reported a narrower-than-expected loss for the second quarter of 2025. The company posted a loss of $0.34 per share, which was significantly better than analysts’ projections of a $0.42 per share loss. Edgewise ended the quarter with a strong cash position of about $594 million as of June 30, 2025, supporting its ongoing clinical programs. Raymond (NSE:RYMD) James reiterated its Strong Buy rating on Edgewise Therapeutics, maintaining a $46 price target after reviewing the company’s second-quarter results and corporate updates. The firm also highlighted that the timing for key catalysts is on track, with the EDG-7500 Phase 2 CIRRUS-HCM Part D results expected in the fourth quarter of 2025. Earlier data from Parts B/C of the trial showed promising efficacy signals, although there were concerns about a potential atrial fibrillation signal in approximately 14% of patients. These developments reflect the company’s financial performance and clinical progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.